Physician profile
Mujtaba F Tapal
NPI 1407841117
$2,990.94
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $363 · 2021: $1,169 · 2022: $832 · 2023: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $707.94 | 2019-2023 | Enbrel, Otezla |
| Pfizer INC. | $493.24 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $337.97 | 2019-2022 | |
| Abbvie INC. | $317.75 | 2019-2023 | Rinvoq |
| Ucb, INC. | $291.01 | 2020-2023 | Cimzia |
| Novartis Pharmaceuticals Corporation | $267.17 | 2019-2023 | |
| Lilly USA, LLC | $136.61 | 2022-2023 | Taltz |
| Janssen Biotech, INC. | $109.19 | 2019-2021 | |
| Horizon Therapeutics Plc | $93.62 | 2021-2022 | |
| Glaxosmithkline, LLC. | $49.59 | 2020-2021 | |
| Celgene Corporation | $38.35 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $35.77 | 2019-2022 | |
| Genzyme Corporation | $23.83 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.81 | 2019 | |
| Radius Health, INC. | $19.17 | 2023 | Tymlos |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $18.66 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mujtaba Tapal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.